Wedbush raised the firm’s price target on Astria Therapeutics (ATXS) to $28 from $27 and keeps an Outperform rating on the shares. The firm says that all development timelines remain on track for lead program navenibart in HAE, with the Phase 3 ALPHA-ORBIT study underway and incorporating two regimens. Potential top-line results remain on track for early 2027. Given the parallels between Takhzyro and navenibart, Wedbush anticipates strong patient interest in the study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics Advances Clinical Trials and Financials
- Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating
- Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating
- Buy Rating for Astria Therapeutics: Promising Clinical Advancements and Strong Financial Position
- Astria Therapeutics, Inc. (ATXS) Q4 Earnings Cheat Sheet
Questions or Comments about the article? Write to editor@tipranks.com